Not finding it? Sign in to also search OpenAlex live.
-
Safety and Tolerability of AZD0466 As Monotherapy for Patients with Advanced Hematologic Malignancies. Results from a Phase I/II Trial2023 Blood conference-abstract Biochemistry, Genetics and Molecular Biology Cell death mechanisms and regulation
Shukaib Arslan, Giovanni Marconi, Giovanni Martinelli, Shaun A. Fleming, Antonio Curti, Shira Naomi Dinner, +19 more
5citations -
Randomized phase III trial of induction chemotherapy followed by chemoradiotherapy or chemotherapy alone for nonresectable locally advanced pancreatic cancer: First results of the CONKO-007 trial.2022 Journal of Clinical Oncology conference-abstract Medicine Pancreatic and Hepatic Oncology Research
Rainer J. Fietkau, Michael B. Ghadimi, Robert Grützmann, Uwe A. Wittel, Lutz Jacobasch, Waldemar Uhl, +14 more
118citations -
Safety and efficacy of INCA033989, a novel first in class mutant calreticulin-specific monoclonal antibody, in patients with essential thrombocythemia2025 Blood conference-abstract Medicine Myeloproliferative Neoplasms: Diagnosis and Treatment Open access
Vikas Gupta, John O Mascarenhas, Haris Ali, David M. Ross, Abdulraheem Yacoub, Tania Jain, +27 more
10citations -
Trial in Progress: A Randomized-Controlled Phase 2 Study Evaluating Venetoclax Plus Azacitidine Versus Intensive Chemotherapy in Adult Patients with Newly Diagnosed, NPM1-Mutated AML - the SAL/AMLCG Vincent Trial
Leo Ruhnke, Christoph Schliemann, Lars R. Fransecky, Björn Steffen, Martin Kaufmann, Andreas Burchert, +26 more
2citations -
High complete response rates, low dropout rate, and low-grade toxicities in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) receiving GLPG5101, a fresh, early memory-enriched CAR T-cell therapy with a 7-day vein-to-vein time: Results from the ATALANTA-1 DLBCL cohort
Joost S.P. Vermaat, Pim G. N. J. Mutsaers, Sébastien Anguille, Maria Theresa Kuipers, Évelyne Willems, Tim J. A. Dekker, +14 more
2citations -
Long Term Outcomes and Renal Response Following Autologous Stem Cell Transplantation for Light Chain Deposition Disease:a Retrospective Study on Behalf of the Cmwp of the EBMT2023 Blood conference-abstract Biochemistry, Genetics and Molecular Biology Amyloidosis: Diagnosis, Treatment, Outcomes
Laurent Garderet, Luuk A. Gras, Linda Köster, Montserrat Rovira, Laure Vincent, Guido Kobbe, +18 more
0citations -
Significant Growth in HCT Use for Haemoglobinopathies in the Last Decade Driven By Sickle Cell Disease across All Ages with Excellent Outcomes: An Analysis of EBMT Haemoglobinopathies Working Party
Josu de la Fuente, Jacques‐Emmanuel Galimard, Arnaud Dalissier, Mohsen Al Zahrani, Ali Debsan Alahmari, Ashrafsadat Mousavi, +14 more
1citations -
Phase 2 Study of Daratumumab (DARA) Plus Bortezomib, Cyclophosphamide, and Dexamethasone (D-VCd) in a Diverse Patient Population with Newly Diagnosed Amyloid Light Chain (AL) Amyloidosis: Aquarius2023 Blood conference-abstract Biochemistry, Genetics and Molecular Biology Amyloidosis: Diagnosis, Treatment, Outcomes
Michael Alan Rosenzweig, Yvonne Adeduni Efebera, Efstathios Kastritis, Brandon Jamaal Blue, Faizi A. Jamal, Monique C. Minnema, +10 more
1citations -
Real-Life Data of Cyclosporine (CsA) Tapering in Patients with Very/ Severe Aplastic Anemia (v/sAA) Treated with Horse Anti-Thymocyte Globulin (hATG/CsA) Suggest Higher Risk of AA Relapse at Cyclosporine Plasma Levels below 100 Nanogram per Milliliter2023 Blood conference-abstract Biochemistry, Genetics and Molecular Biology Blood disorders and treatments
Jeanette Walter, Kim Kricheldorf, Yannic Schumacher, Susanne Isfort, Jörg Chromik, Beatrice Drexler, +4 more
2citations -
Seven-Day Vein-to-Vein Point-of-Care Manufactured CD19 CAR T Cells (GLPG5201) in Relapsed/Refractory CLL/SLL Including Richter's Transformation: Results from the Phase 1 Euplagia-1 Trial
Natalia Tovar, Valentín Ortiz‐Maldonado, Núria Martínez‐Cibrián, Sergi Betriu, Daniel Esteban, Ana Triguero, +5 more
5citations -
Allogeneic Hematopoietic Cell Transplantation for Vexas Syndrome: Results of a Multicenter Study from the Chronic Malignancies and Autoimmune Disease Working Parties of the EBMT
Carmelo Gurnari, Linda Köster, Laurien G.A. Baaij, Maël Heiblig, Ibrahim Yakoub‐Agha, Jakob Robert Passweg, +18 more
5citations -
Polb 001, an Oral Broad-Spectrum Anti-Inflammatory with the Potential to Prevent Cytokine Release Syndrome (CRS)2023 Blood conference-abstract Immunology and Microbiology Immunotoxicology and immune responses cited by 3 patents
Emma J Searle, Liam Friel Tremble, Rakesh Popat, Digna T. de Bruin, Matthijs Moerland, Brendan Martin Buckley
3citations -
High complete response rates and minimal residual disease (MRD) negativity, with durable responses, in high-risk mantle cell lymphoma (MCL) with GLPG5101, a fresh, early memory-enriched CAR T-cell therapy with a 7-day vein-to-vein time: Results from the ATALANTA-1 MCL cohort
Marie José Kersten, Joost S.P. Vermaat, Pim G. N. J. Mutsaers, Maria Theresa Kuipers, Évelyne Willems, Sébastien Anguille, +14 more
3citations -
Randomized Phase II Study of All-Trans Retinoic Acid and Valproic Acid Added to Decitabine in Newly Diagnosed Elderly AML Patients (DECIDER trial): Predictive Impact of TP53 Status
Heiko Becker, Claudia Schmoor, Olga Grishina, Dietmar Pfeifer, Dennis Zimmer, Martina Margrit Crysandt, +27 more
3citations -
Sustained Improvement in Health-Related Quality of Life in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Daratumumab, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone: Update of the Phase 3 MAIA Trial
Aurore Perrot, Thierry T.F. Facon, Shaji Kunnathu Kumar, Torben Plesner, Robert Zygmunt Orlowski, Philippe Moreau, +24 more
1citations
24 results